NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam Pharma" or the "Company"), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.
荷蘭納爾登和邁阿密，9月1日2023年20日(環球網)--臨床階段生物製藥公司新阿姆斯特丹製藥公司(納斯達克代碼：NAMS或“新阿姆斯特丹製藥公司”或“公司”)今天宣佈，紐阿姆斯特丹製藥公司首席執行官邁克爾·戴維森將參加2023年9月27日(星期三)坎託·菲茨傑拉德全球醫療會議的爐邊聊天。該公司是一家臨床階段的生物製藥公司，為低密度脂蛋白膽固醇(“LDL-C”)殘留升高的心血管疾病高危患者開發口服非他汀類藥物2023年下午1：50Et.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company's website.
爐邊談話的網路直播將通過新阿姆斯特丹製藥公司網站的投資者關系部分進行，網址為ir.newamsterDampharma.com。在網路直播之後，將在公司網站上進行存檔重播。
About NewAmsterdam
關於新阿姆斯特丹
Based in the Netherlands, NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently adequate or well tolerated. We seek to fill a significant unmet need for a safe, cost-effective and convenient LDL-lowering therapy as an adjunct to statins, a class of lipid-lowering medications that are the current standard of care for high-risk CVD patients with high cholesterol. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.
總部設在荷蘭的新阿姆斯特丹公司(納斯達克代碼：NAMS)是一家臨床階段的生物製藥公司，其使命是改善患有代謝性疾病的人群的患者護理，這些人群目前批准的治療方法不夠充分或耐受性不佳。我們尋求滿足一個重要的未得到滿足的需求，即作為他汀類藥物的補充，安全、成本效益高和方便的降低低密度脂蛋白療法，他汀類藥物是一類降脂藥物，目前是高風險心血管疾病高膽固醇患者的護理標準。新阿姆斯特丹正在研究ObicetRapib，一種口服、低劑量、每天一次的CETP抑制劑，作為高風險心血管疾病患者最大耐受性他汀類藥物的首選降低低密度脂蛋白的輔助療法。
Company Contact
公司聯繫人
Matthew Philippe
P: 917-882-7512
matthew.philippe@newamsterdampharma.com
馬修·菲利普
電話：917-882-7512
郵箱：matthew.philippe@newamsterDampharma.com
Media Contact
媒體聯繫人
Spectrum Science on behalf of NewAmsterdam
Jenn Gordon
P: 1-202-957-7795
jgordon@spectrumscience.com
代表新阿姆斯特丹的光譜科學
珍妮·戈登
電話：1-202-957-7795
郵箱：jgordon@spectrumcerence.com
Investor Contact
投資者聯繫方式
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com
代表新阿姆斯特丹的斯特恩投資者關係
漢娜·德雷謝維奇
電話：1212-362-1200
郵箱：hannah.deresiewicz@sternir.com
譯文內容由第三人軟體翻譯。